A study to investigate longer term dosing of ARB-1467 in combination with tenofovir as well as pegylated interferon

Trial Profile

A study to investigate longer term dosing of ARB-1467 in combination with tenofovir as well as pegylated interferon

Planning
Phase of Trial: Phase II

Latest Information Update: 02 Nov 2017

At a glance

  • Drugs ARB 1467 (Primary) ; Interferon; Tenofovir
  • Indications Hepatitis B
  • Focus Proof of concept; Therapeutic Use
  • Most Recent Events

    • 02 Nov 2017 According to an Arbutus Biopharma media release, the company expects to initiate this study in the fourth quarter of 2017; also interim results are expected in the second half of 2018, followed by final results in 2019.
    • 03 Aug 2017 According to an Arbutus Biopharma media release, this trial is expected to initiate in the fourth quarter of 2017.
    • 25 Apr 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top